Promising new therapies for the treatment of hypercholesterolemia

References

• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. American college of cardiology/American heart association task force on practice guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129:S49–73.
   PubMedGoogle Scholar
• Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low density lipoprotein cholesterol and high sensitivity c-reactive protein targets more frequent with the addition of Ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132:1224–1233. doi:10.1161/CIRCULATIONAHA.115.018381.
   PubMed Web of Science ®Google Scholar
• Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26–35. doi:10.1016/j.clinthera.2006.01.005.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. doi:10.1056/NEJMoa054013.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156. doi:10.1038/ng1161.
   PubMed Web of Science ®Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161–165. doi:10.1038/ng1509.
   PubMed Web of Science ®Google Scholar
• Bjørklund MM, Hollensen AK, Hagensen MK, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014;114:1684–1689.
   PubMed Web of Science ®Google Scholar
• Nohturfft A, DeBose‐Boyd RA, Scheek S, et al. Sterols regulate cycling of SREBP cleavage‐activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci USA. 1999;96:11235–11240.
   PubMed Web of Science ®Google Scholar
• Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006;26:1094–1100.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35:1082–1098. doi:10.1016/j.clinthera.2013.06.019.
   PubMed Web of Science ®Google Scholar
• Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106:9820–9825. doi:10.1073/pnas.0903849106.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531–2540. doi:10.1016/j.jacc.2014.03.018.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. LAPLACE-2 investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870–1882. doi:10.1001/jama.2014.4030.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340. doi:10.1016/S0140-6736(14)61399-4.
   PubMed Web of Science ®Google Scholar
• Walton TA, Nishtar S, Lumb PJ, et al. Pro-protein convertase subtilisin/kexin 9 oncentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. Int J Clin Pract. 2015;69:738–742. doi:10.1111/ijcp.12615.
   PubMed Web of Science ®Google Scholar
• Kuhnast S, van der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55:2103–2112. doi:10.1194/jlr.M041038.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499. doi:10.1056/NEJMoa1501031.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-label study of long-term evaluation against LDL cholesterol (OSLER) investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509. doi:10.1056/NEJMoa1500858.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. The DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–1819. doi:10.1056/NEJMoa1316222.
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Honarpour N, Xue A, et al. Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III yukawa 2 study. J Am Coll Cardiol. 2015;65(A1369). doi:10.1016/j.jacc.2014.11.040.
   Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial ofevolocumab. J Am Coll Cardiol. 2014;63:2541–2548. doi:10.1016/j.jacc.2014.03.019.
   PubMed Web of Science ®Google Scholar
• Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) [ClinicalTrials.gov identifier: NCT01764633]; [updated 2015 Oct 30]. Available from: http://clinicaltrials.gov/show/NCT01764633
   Google Scholar
• Toth PP, Sattar N, Genest J, et al. A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145). J Am Coll Cardiol. 2015;65(A1351). doi:10.1016/j.jacc.2014.11.040.
   Web of Science ®Google Scholar
• Roth EM, Taskinen M, Ginsberg H, et al. A 24-week study of alirocumab as monotherapy versus ezetimibe: the first Phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J Am Coll Cardiol. 2014;63(12):A1370. doi:10.1016/S0735-1097(14)61370-X.
   Web of Science ®Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Circulation. 2014;130:2108–2109.
   Web of Science ®Google Scholar
• Sanofi. Phase III study to evaluate alirocumab in patients with hypercholesterolemia not treated with a statin (ODYSSEY CHOICE II) [ClinicalTrials.gov identifier: NCT02023879]; [updated 2015 Oct 30]. Available from https://clinicaltrials.gov/ct2/show/NCT02023879
   Google Scholar
• Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906–915. doi:10.1016/j.ahj.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186–1194. doi:10.1093/eurheartj/ehv028.
   PubMed Web of Science ®Google Scholar
• Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100:3140–3148. doi:10.1210/jc.2014-3941.
   PubMed Web of Science ®Google Scholar
• Bays H, Farnier M, Gaudet D, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Circulation. 2015;130:2118–2119.
   Web of Science ®Google Scholar
• Regeneron Pharmaceuticals Inc, Sanofi-aventis. PRALUENT (alirocumab): US prescribing Information; 2015. [updated 2015 Oct 30]. Available from http://www.regeneron.com/Praluent/Praluent-fpi.pdf
   Google Scholar
• Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212–1221. doi:10.1016/j.amjcard.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Pfizer. The evaluation of PF-04950615 (RN316), in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1) [ClinicalTrials.gov identifier: NCT01975376];[updated 2015 Oct 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01975376
   Google Scholar
• Pfizer. The evaluation of PF-04950615 (RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2) [ClinicalTrials.gov identifier: NCT01975389]; [updated 2015 Oct 30] Available from: https://clinicaltrials.gov/ct2/show/results/NCT01975389
   Google Scholar
• Kastelein J, Nissen S, Rader D, et al. Safety and efficacy of LY3015014, a new monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) with an inherently longer duration of action, in patients with primary hypercholesterolemia: A randomized, placebo-controlled, dose-ranging, phase 2 study. J Am Coll Cardiol. 2015;65(10_S). doi:10.1016/j.jacc.2014.11.040.
   Web of Science ®Google Scholar
• Tingley W, Luca D, Leabman M, et al. Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. Eur Heart J. 2013;34(Suppl 1). doi:10.1093/eurheartj/eht309.P4183.
   Google Scholar
• Mitchell T, Chao G, Sitkoffv D. Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for LDL lowering. J Pharmacol Exp Ther. 2014;350:412–424. doi:10.1124/jpet.114.214221.
   PubMed Web of Science ®Google Scholar
• Stein EA, Kasichayanula S, Turner T, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol. 2014;63(12 Suppl):A172. doi:10.1016/S0735-1097(14)61372-3.
   Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration ofserum LDL cholesterol in healthy volunteers: a randomised, singleblind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60–68. doi:10.1016/S0140-6736(13)61612-8.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein with incidence of cardiovascular disease in the community. Circulation. 2009;120:14–20. doi:10.1161/CIRCULATIONAHA.109.872705.
   Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515. doi:10.1056/NEJMoa031766.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. doi:10.1056/NEJMoa0706628.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316. doi:10.1056/NEJMc063190.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630. doi:10.1056/NEJMc063190.
   PubMed Web of Science ®Google Scholar
• Barter P. Lessons learned from the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Am J Cardiol. 2009;104:10E–15E. doi:10.1016/j.amjcard.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085–1088. doi:10.1016/j.amjcard.2005.01.026.
   PubMed Web of Science ®Google Scholar
• Schwartz G, Chaitman BBR, Holme IM, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099. doi:10.1056/NEJMoa1206797.
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, et al. dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378:1547–1559. doi:10.1016/S0140-6736(11)60984-7.
   PubMed Web of Science ®Google Scholar
• Lu¨scher TF, Taddei S, Kaski J-C, et al. dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857–865. doi:10.1093/eurheartj/ehs019.
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360. doi:10.1016/j.ahj.2008.09.022.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. Determining the Efficacy and Tolerability Investigators. N Engl J Med. 2010;363:2406–2415. doi:10.1056/NEJMoa1009744.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. [ClinicalTrials.gov identifier: NCT01252953]; [updated 2015 Oct 30]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01252953
   Google Scholar
• Gotto GM, Phil CP, Cannon MD, et al. Evaluation of lipids, drug concentrations, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76–83. doi:10.1016/j.amjcard.2013.08.041.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. A randomized controlled trial. JAMA. 2011;306:2099–2109. doi:10.1001/jama.2011.1649.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE) [ClinicalTrials.gov identifier: NCT01687998]; [Last accessed 2015 October 30]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01687998
   Google Scholar
• Nicholls SJ, Gordon A, Johannson J, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181–187. doi:10.1007/s10557-012-6373-5.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET Protein Inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016;16:55–65.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134–151. doi:10.1194/jlr.M030528.
   PubMed Web of Science ®Google Scholar
• Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–699.
   PubMed Web of Science ®Google Scholar
• Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014;25:309–315. doi:10.1097/MOL.0000000000000091.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, MacDougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676–683.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomized, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283–2292.
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006. doi:10.1371/journal.pone.0049006.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76:269–276.
   PubMed Web of Science ®Google Scholar
• Genzyme Corp. Kynamro (mipomersen sodium): U.S. Prescribing Information; 2013. [Last accessed 2015 Oct 30]. Available from: https://www.genzyme.com/Products/~/media/B866EE59A7C14916BFBFB4ECAA1C7087.pdf
   Google Scholar
• Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–156.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, Du Toit Theron H, et al. Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46.
   PubMed Web of Science ®Google Scholar